Andelyn Biosciences Partners with Hubble Therapeutics for AAV Production
Andelyn Biosciences, Inc., a prominent cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has entered into a partnership with Hubble Therapeutics, LLC. This collaboration focuses on the manufacturing of clinical-grade adeno-associated virus (AAV) utilizing Andelyn's advanced suspension AAV Curator™ Platform, aimed at treating Leber Congenital Amaurosis 16 (LCA16).
Understanding LCA16 and Its Impact
LCA16 is characterized as a severe retinal dystrophy caused by mutations in the KCNJ13 gene, which significantly affects vision starting in early childhood. Children affected by this condition often show visual impairments within the first five years of life, which gradually leads to complete blindness. The FDA has recognized the urgency of this issue, granting HUB-101 both Rare Pediatric Disease Designation and Orphan Disease Designation. By optimizing and scaling up the manufacturing process for HUB-101, Andelyn aims to assist in the creation of GMP-grade plasmids and vectors, incorporating normal KCNJ13 gene copies.
Commitment to Pediatric and Adult Patients
Jeff Sabados, President of Hubble Therapeutics LLC, emphasized the strategic importance of finding top-tier partners like Andelyn Biosciences. He noted the commitment shown by Andelyn to the development of gene therapy solutions for both adult and pediatric patients grappling with LCA16. This partnership underscores a shared vision of alleviating the burdens faced by families impacted by this genetic condition.
The Role of Andelyn Biosciences
Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, expressed enthusiasm about their contribution to the HUB-101 project. He highlighted the importance of their role in providing the necessary clinical-grade materials while aiming to foster a pathway that demonstrates clinical benefits for patients involved in the LCA16 study. Andelyn's reputation as a leading and reliable CDMO is instrumental in accelerating various gene therapy programs, potentially offering new hope for individuals afflicted by debilitating diseases.
About Andelyn Biosciences, Inc.
Andelyn Biosciences operates as a comprehensive CDMO specializing in cell and gene therapies. With over two decades of expertise, the organization has successfully produced cGMP materials for more than 450 clinical batches and contributed to 75 global clinical trials. Situated across three facilities, Andelyn provides a full range of services to clients, from plasmid engineering and manufacturing to cGMP clinical and commercial production. Andelyn can integrate advanced technology with their configurable, data-driven AAV Curator™ Platform to enhance program efficiency and output quality.
About Hubble Therapeutics, LLC
Hubble Therapeutics, LLC, or HubbleTx, is a dedicated biotechnology company focused on developing cutting-edge gene therapy solutions, particularly for LCA16. Originating from rigorous research conducted at the University of Wisconsin-Madison, HubbleTX aims to tackle this debilitating condition by developing therapies designed to restore vision and improve patient quality of life. Their collaborative approach, combined with a commitment to clinical excellence, positions them uniquely to make significant advancements in this vital area of healthcare.
Frequently Asked Questions
What is the main focus of the partnership between Andelyn and Hubble?
The partnership aims to manufacture clinical-grade AAV for the treatment of Leber Congenital Amaurosis 16 (LCA16).
What is LCA16?
LCA16 is a severe retinal dystrophy caused by mutations in the KCNJ13 gene, leading to vision loss and gradual blindness.
How does Andelyn Biosciences contribute to this project?
Andelyn provides expertise in manufacturing AAV and developing GMP-grade plasmids necessary for the clinical trials of HUB-101.
What designations has HUB-101 received?
HUB-101 has been granted Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA.
What is the goal of Hubble Therapeutics?
Hubble Therapeutics aims to restore vision and improve life quality for individuals affected by LCA16 through innovative gene therapy solutions.
